Cargando…

Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir

Molecular dynamics simulations are performed to investigate the dynamic properties of wild-type HIV-1 protease and its two multi-drug-resistant variants (Flap + (L10I/G48V/I54V/V82A) and Act (V82T/I84V)) as well as their binding with APV and DRV inhibitors. The hydrophobic interactions between flap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yuqi, Wang, Jinan, Shao, Qiang, Shi, Jiye, Zhu, Weiliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444956/ https://www.ncbi.nlm.nih.gov/pubmed/26012849 http://dx.doi.org/10.1038/srep10517

Ejemplares similares

Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by Molecular Dynamics Simulations
por: Chen, Jianzhong, et al.
Publicado: (2014)

Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins
por: Halder, Umesh C.
Publicado: (2021)

The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.
por: Bawdon, R E
Publicado: (1998)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
por: Nadler, Jeffrey P, et al.
Publicado: (2003)

The effects of organic solvents on the folding pathway and associated thermodynamics of proteins: a microscopic view
por: Yu, Yuqi, et al.
Publicado: (2016)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

The structural, dynamic, and thermodynamic basis of darunavir resistance of a heavily mutated HIV-1 protease using molecular dynamics simulation
por: Shabanpour, Yaser, et al.
Publicado: (2022)

The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes
por: Blaine-Sauer, Simon, et al.
Publicado: (2023)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages
por: Borrajo, Ana, et al.
Publicado: (2017)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Amprenavir inhibits pepsin‐mediated laryngeal epithelial disruption and E‐cadherin cleavage in vitro
por: Samuels, Tina L., et al.
Publicado: (2023)

The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms
por: Gao, Xiaobo, et al.
Publicado: (2019)

Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance
por: Liu, Zhanglong, et al.
Publicado: (2020)

Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance
por: Nakashima, Masaaki, et al.
Publicado: (2016)

Evaluation of novel protease inhibitors against darunavir‐resistant variants of HIV type 1
por: Inoue, Mari, et al.
Publicado: (2016)

Publisher Correction: The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms
por: Gao, Xiaobo, et al.
Publicado: (2020)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2016)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
por: Chavda, Vivek P., et al.
Publicado: (2021)

The L33F darunavir resistance mutation acts as a molecular anchor reducing the flexibility of the HIV-1 protease 30s and 80s loops
por: Kuiper, Benjamin D., et al.
Publicado: (2015)

Higher plasma drug levels in elderly people living with HIV treated with darunavir
por: Tyrberg, Erika, et al.
Publicado: (2021)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
por: Mishra, Tulsidas, et al.
Publicado: (2014)

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
por: Fenley, Juliana de C., et al.
Publicado: (2022)

In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex
por: Buitrón-González, Ivonne, et al.
Publicado: (2021)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

Correction: Higher plasma drug levels in elderly people living with HIV treated with darunavir
Publicado: (2021)

Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment
por: Kumar, Asit, et al.
Publicado: (2022)

Drug Resistance Mutations Alter Dynamics of Inhibitor-Bound HIV-1 Protease
por: Cai, Yufeng, et al.
Publicado: (2014)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
por: Squillace, Nicola, et al.
Publicado: (2018)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mro3cu1rtbv61up84326nleqaf